newsfilter
← Latest News
GlobeNewswire·

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RANI
  • Rani Therapeutics granted a stock option for 2,000,000 Class A shares to Nicholas Maestas as an inducement for his role as Chief Financial Officer.
  • The option was granted on July 17, 2026, with an exercise price of $0.6973 per share, matching the closing price on the grant date.
  • The option has a ten-year term \& vests over four years, with 25% vesting on the first anniversary of employment \& the remainder vesting in equal monthly installments over the next 36 months.
  • The grant was approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4) \& is subject to the 2026 Equity Inducement Plan.
  • Rani Therapeutics is a clinical-stage company developing the RaniPill capsule to enable oral delivery of biologics \& drugs.